Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.

Caccamo A, Majumder S, Richardson A, Strong R, Oddo S.

J Biol Chem. 2010 Apr 23;285(17):13107-20. doi: 10.1074/jbc.M110.100420. Epub 2010 Feb 23.

2.

mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.

Caccamo A, Magrì A, Medina DX, Wisely EV, López-Aranda MF, Silva AJ, Oddo S.

Aging Cell. 2013 Jun;12(3):370-80. doi: 10.1111/acel.12057. Epub 2013 Mar 24.

3.

Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?

Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi SH, Tan Y.

J Neurosci Res. 2012 Jun;90(6):1105-18. doi: 10.1002/jnr.23011. Epub 2012 Feb 16. Review.

PMID:
22344941
4.

Activation of mTOR signaling leads to orthopedic surgery-induced cognitive decline in mice through β-amyloid accumulation and tau phosphorylation.

Shen W, Lu K, Wang J, Wu A, Yue Y.

Mol Med Rep. 2016 Oct;14(4):3925-34. doi: 10.3892/mmr.2016.5700. Epub 2016 Sep 1.

PMID:
27599409
5.

Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.

Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, Perluigi M, Butterfield DA.

J Neurochem. 2015 Jun;133(5):739-49. doi: 10.1111/jnc.13037. Epub 2015 Feb 26.

6.

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.

Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V.

PLoS One. 2010 Apr 1;5(4):e9979. doi: 10.1371/journal.pone.0009979. Erratum in: PLoS One. 2011;6(11). doi:10.1371/annotation/05c1b976-7eab-4154-808d-0526e604b8eb.

7.

Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.

Caccamo A, De Pinto V, Messina A, Branca C, Oddo S.

J Neurosci. 2014 Jun 4;34(23):7988-98. doi: 10.1523/JNEUROSCI.0777-14.2014.

8.

The role of mTOR signaling in Alzheimer disease.

Oddo S.

Front Biosci (Schol Ed). 2012 Jan 1;4:941-52. Review.

9.

Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism.

Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magrí A, Oddo S.

J Biol Chem. 2011 Mar 18;286(11):8924-32. doi: 10.1074/jbc.M110.180638. Epub 2011 Jan 25.

10.

Tripchlorolide improves cognitive deficits by reducing amyloid β and upregulating synapse-related proteins in a transgenic model of Alzheimer's Disease.

Zeng Y, Zhang J, Zhu Y, Zhang J, Shen H, Lu J, Pan X, Lin N, Dai X, Zhou M, Chen X.

J Neurochem. 2015 Apr;133(1):38-52. doi: 10.1111/jnc.13056. Epub 2015 Mar 8.

11.

Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.

Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, Messina A, Huang Z, Wu J, Oddo S.

J Neurosci. 2015 Oct 14;35(41):14042-56. doi: 10.1523/JNEUROSCI.2781-15.2015.

12.

Variations in the effects on synthesis of amyloid beta protein in modulated autophagic conditions.

Makioka K, Yamazaki T, Kakuda S, Okamoto K.

Neurol Res. 2009 Nov;31(9):959-68. doi: 10.1179/174313209X395463. Epub 2009 Feb 11.

PMID:
19215663
13.

Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer's disease.

Jiang T, Yu JT, Zhu XC, Tan MS, Wang HF, Cao L, Zhang QQ, Shi JQ, Gao L, Qin H, Zhang YD, Tan L.

Pharmacol Res. 2014 Mar;81:54-63. doi: 10.1016/j.phrs.2014.02.008. Epub 2014 Mar 3.

PMID:
24602800
14.

Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice.

Wang C, Zhang X, Teng Z, Zhang T, Li Y.

Eur J Pharmacol. 2014 Oct 5;740:312-20. doi: 10.1016/j.ejphar.2014.06.051. Epub 2014 Jul 17.

PMID:
25041840
15.
16.

Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology.

Orr ME, Salinas A, Buffenstein R, Oddo S.

Neurobiol Aging. 2014 Jun;35(6):1233-42. doi: 10.1016/j.neurobiolaging.2013.12.006. Epub 2013 Dec 14.

17.

Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies.

Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H.

J Biol Chem. 2013 Jan 11;288(2):1295-306. doi: 10.1074/jbc.M112.409250. Epub 2012 Nov 15.

18.

Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice.

McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A.

Brain Res. 2008 May 1;1207:225-36. doi: 10.1016/j.brainres.2008.01.095. Epub 2008 Feb 16.

19.
20.

Soluble aβ promotes wild-type tau pathology in vivo.

Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, LaFerla FM.

J Neurosci. 2012 Nov 28;32(48):17345-50. doi: 10.1523/JNEUROSCI.0172-12.2012.

Supplemental Content

Support Center